See the DrugPatentWatch profile for kadcyla

The Commercial Manufacturing Steps of Kadcyla: A Comprehensive Overview

Kadcyla, also known as ado-trastuzumab emtansine, is a targeted cancer therapy used to treat HER2-positive breast cancer. Developed by Genentech, a member of the Roche Group, Kadcyla is a combination of the monoclonal antibody trastuzumab and the microtubule inhibitor DM1. In this article, we will delve into the possible commercial manufacturing steps of Kadcyla, exploring the process from raw material sourcing to final product packaging.

Raw Material Sourcing

The manufacturing process of Kadcyla begins with the sourcing of high-quality raw materials, including trastuzumab, DM1, and other excipients. Trastuzumab is a humanized monoclonal antibody produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells. DM1, on the other hand, is a microtubule inhibitor derived from the marine sponge Eudistoma olivaceum. The raw materials are sourced from reputable suppliers and undergo rigorous testing to ensure their quality and purity.

Manufacturing Process

The manufacturing process of Kadcyla involves several steps, including:

Step 1: Trastuzumab Production

Trastuzumab is produced through recombinant DNA technology in CHO cells. The cells are cultured in a controlled environment and fed a nutrient-rich medium. The trastuzumab is then harvested, purified, and formulated into a solution.

Step 2: DM1 Production

DM1 is produced through a fermentation process using a microorganism such as E. coli. The microorganism is cultured in a controlled environment and fed a nutrient-rich medium. The DM1 is then harvested, purified, and formulated into a solution.

Step 3: Conjugation

The trastuzumab and DM1 solutions are then conjugated together using a linker molecule. This process involves the attachment of the DM1 molecule to the trastuzumab antibody through a covalent bond.

Step 4: Purification

The conjugated product is then purified using a series of chromatography steps to remove impurities and excess linker molecules.

Step 5: Formulation

The purified conjugated product is then formulated into a solution or lyophilized powder.

Step 6: Packaging

The final product is then packaged into vials or syringes and sterilized using aseptic techniques.

Quality Control

Throughout the manufacturing process, quality control measures are implemented to ensure the quality and purity of the final product. This includes testing for potency, purity, and stability, as well as testing for contaminants and impurities.

Commercial Manufacturing

Kadcyla is manufactured by Genentech at their commercial-scale facilities in the United States. The manufacturing process is designed to ensure consistency and quality, with multiple quality control checks throughout the process.

Conclusion

In conclusion, the commercial manufacturing steps of Kadcyla involve a complex process of raw material sourcing, production, conjugation, purification, formulation, and packaging. Quality control measures are implemented throughout the process to ensure the quality and purity of the final product.

Key Takeaways

* Kadcyla is a targeted cancer therapy used to treat HER2-positive breast cancer.
* The manufacturing process involves the sourcing of high-quality raw materials, including trastuzumab and DM1.
* The process includes multiple steps, including production, conjugation, purification, formulation, and packaging.
* Quality control measures are implemented throughout the process to ensure the quality and purity of the final product.

FAQs

1. What is Kadcyla used to treat?
Kadcyla is used to treat HER2-positive breast cancer.
2. What are the raw materials used in the manufacturing process of Kadcyla?
The raw materials used in the manufacturing process of Kadcyla include trastuzumab, DM1, and other excipients.
3. How is trastuzumab produced?
Trastuzumab is produced through recombinant DNA technology in CHO cells.
4. What is DM1?
DM1 is a microtubule inhibitor derived from the marine sponge Eudistoma olivaceum.
5. What is the conjugation process?
The conjugation process involves the attachment of the DM1 molecule to the trastuzumab antibody through a covalent bond.

Sources

1. Genentech. (n.d.). Kadcyla. Retrieved from <https://www.gene.com/patients/treatments-and-resources/kadcyla>
2. DrugPatentWatch.com. (n.d.). Ado-trastuzumab emtansine (Kadcyla). Retrieved from <https://www.drugpatentwatch.com/drug/ado-trastuzumab-emtansine-kadcyla>
3. Roche. (n.d.). Kadcyla. Retrieved from <https://www.roche.com/kadcyla>
4. National Cancer Institute. (n.d.). Kadcyla. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/kadcyla>
5. European Medicines Agency. (n.d.). Kadcyla. Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla>